The short version of IRAP fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Salting out (also known as salt-induced precipitation, salt fractionation, anti-solvent crystallization, precipitation crystallization, or drowning out) is a purification technique that utilizes the reduced solubility of certain molecules in a solution of very high ionic strength. Salting out is typically used to precipitate large biomolecules, such as proteins or DNA. Because the salt concentration needed for a given protein to precipitate out of the solution differs from protein to protein, a specific salt concentration can be used to precipitate a target protein. This process is also used to concentrate dilute solutions of proteins. Dialysis can be used to remove the salt if needed.
==== Separatory funnels ==== Separatory funnels, colloquially called a "sep funnel," are commonly used for small-scale extractions in research or teaching labs. To perform an extraction, two immiscible liquids, typically an aqeuous solution and an organic solvent, are added to the sep funnel. The sep funnel is then shaken using appropriate technique to increase the area of contact between the two phases to aid extraction. After the two layers are allowed to settle and separate, each layer is drained from the bottom of the sep funnel into separate containers. Multiple extractions may be performed on the same reaction mixture to increase product recovery. After extraction, the extract phase can be used for further processing Partitioning of organic compounds between the organic and aqueous phases can be controlled by adjusting the pH of the aqeuous phase. For example, increasing the pH of the aqueous solution will deprotanate organic acids, giving them a negative charge that favors partitioning into polar solvents like water. Adding a strong acid to decrease pH can have the opposite effect, neutralizing conjugate bases to form neutral compounds that can partition more easily into the organic phase. This technique can be used in teaching labs to extract compounds like caffeine from coffee or tea using ethyl acetate as the organic extractant.
In March 2020, it was announced that a secret six-month DEA operation known as "Operation Python" resulted in the arrest of 600 CJNG operatives and the seizure of $20 million in cash. The number of arrests was revised to 750, though it was still thought the CJNG could still partake in trafficking within the U.S. so long as it keeps its base of operations in Mexico. On 2 June 2020, Mexico's Financial Intelligence Unit released a statement revealing that as a result of joint operation with the DEA, the agency was able to locate "a large number of members of said criminal group, as well as its largest financial operators and companies used in money laundering". Mexico's Financial Intelligence Unit, a part of the finance ministry tasked with combating and preventing money laundering, then managed to have 1,770 bank accounts of CJNG-linked individuals frozen. Bank accounts to 16 CJNG-linked companies and two trusts linked to the CJNG were frozen as well. The move came after armed assailants stormed a live CJNG-provided concert on 29 May 2020 in the Veracruz city of Tierra Blanca, injuring two and killing six. Those killed included the regional CJNG leader, and also owner of the local El Sol de Tierra Blanca newspaper, Francisco Navarette Serna and the full lineup of La Calle, the band Serna was performing with. On 3 June, it was reported the amount of CJNG-linked assets which were frozen totaled $1.1 billion.
Sources: en.wikipedia.org
The conjugate addition between Ethyl crotonate [623-70-1][10544-63-5] (1) and dimethylamine gives Ethyl 3-(Dimethylamino)Butanoate [85118-28-1] (2). Grignard reaction with 2-Bromothiophene [1003-09-4] (3) gives (4). Dehydration in acid completed the synthesis (5).
=== Capsule === The capsule consists of 20-70 concentrically-arranged connective tissue lamellae around the axon terminal at its center, forming a structure much like an onion. The capsule consists of fibroblasts and fibrous connective tissue (mainly Type IV and Type II collagen network), separated by gelatinous material, more than 92% of which is water. It presents a whorled pattern on micrographs. If the corpuscle's capsule is experimentally removed, the divested axon terminal becomes slowly adapting. The capsule is therefore responsible for the corpuscle's selectivity for high-frequency stimuli. This is a result of the slippery lamellae sliding past each other when the corpuscle is structurally deformed by external pressure so that effects of sustained pressure are soon dissipated by the lamellae, abolishing deformation of the central axon terminal itself. The capsule thus acts as a physiological high-pass filter.
==== The four noble truths ==== According to early suttas like AN 3.61, the second and third noble truths of the four noble truths are directly correlated to the principle of dependent origination. The second truth applies dependent origination in a direct order, while the third truth applies it in inverse order. Furthermore, according to SN 12.28, the noble eight-fold path (the fourth noble truth) is the path which leads to the cessation of the twelve links of dependent origination and as such is the "best of all conditioned states" (AN.II.34). Therefore, according to Harvey, the four noble truths "can be seen as an application of the principle of conditioned co-arising focused particularly on dukkha."
Although the most important members of each family are tabulated here, some species may express additional chaperones, co-chaperones, and heat shock proteins not listed. In addition, many of these proteins may have multiple splice variants (Hsp90α and Hsp90β, for instance) or conflicts of nomenclature (Hsp72 is sometimes called Hsp70).
Sources: en.wikipedia.org
James Henry Wiggin, as an editor and literary adviser. The issue of how much Wiggin contributed to Science and Health is controversial. A former Unitarian clergyman, he was the book's editor from the 16th edition in 1886 until the 50th in 1891—22 editions appeared between 1886 and 1888 alone—and according to his literary executor, speaking after Wiggin's death, said he had rewritten it. Robert Peel wrote that Wiggin had "toned up" Eddy's style, but had not affected her thinking. In a letter to Wiggin in July 1886, Eddy wrote: "Never change my meaning, only bring it out." Eddy continued to revise the book until her death in 1910. In 1902 she added a chapter, "Fruitage," recounting healing testimonies from the Christian Science Journal and Christian Science Sentinel. There were over 400 editions (the final ran to 18 chapters and 600 pages), seven of them major revisions, according to Gottschalk, and members were encouraged to buy them all. Other income derived from the sale of rings and brooches, pictures of Eddy, and in 1889 the Mary Baker Eddy souvenir spoon; Eddy asked every Christian Scientist to buy at least one, or a dozen if they could afford to. When the copyright on Science and Health expired in 1971, the church persuaded Congress to extend it to 2046. The bill was supported by two of President Richard Nixon's aides, Christian Scientists H. R. Haldeman and John Ehrlichman. The law was overturned as unconstitutional in 1987, after a challenge by United Christian Scientists, an independent group. By 2001 Science and Health had sold over nine million copies.
== Protective tissues == Within motor nerves, each axon is wrapped by the endoneurium, which is a layer of connective tissue that surrounds the myelin sheath. Bundles of axons are called fascicles, which are wrapped in perineurium. All of the fascicles wrapped in the perineurium are wound together and wrapped by a final layer of connective tissue known as the epineurium. These protective tissues defend nerves from injury, pathogens and help to maintain nerve function. Layers of connective tissue maintain the rate at which nerves conduct action potentials.
== Prognosis == Sickle cell disease is most prevalent in sub-saharan Africa. In areas without healthcare infrastructure, it is estimated that between 50% and 90% of children born with the disease die before the age of 5 years. In contrast, life expectancy in the United States in 2010–2020 was 43 years and in the UK 67 years.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.